Key Dates

Related Announcements

RFA-DA-22-032- HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice informs potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately, in RFA-DA-22-032 "HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)".

The following text has been added to reflect NIAID's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)

Assistance Listing Number(s)

93.855

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

NIAID Interest

In addition to the ongoing opioid use and overdose crisis, synthetic opioids, such as fentanyl, carfentanil, acetylfentanyl, sufentanil, remifentanil, lofentanil, and alfentanil, have also been designated by the U.S. Government as highly toxic chemicals of concern where medical countermeasures (MCMs) are urgently needed to advance national biosecurity, medical and public health preparedness for, response to, and recovery from disasters and mass casualty emergencies resulting from deliberate and/or accidental release.

Through the Chemical Countermeasures Research Program (CCRP), the NIAID supports the research and early stage development of MCMs to treat and/or prevent serious morbidities and mortality during or after high consequence, public health emergencies involving the release of highly toxic chemicals that may result in mass civilian casualty. To learn more, see The National Institutes of Health Chemical Countermeasures Research Program (NIH CCRP): A collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people, published in Drug Development Research.

In partnership with the NIDA Chemistry and Pharmacology Branch (CP), the CCRP is particularly interested in identifying novel therapeutic targets and approaches that:

1. Will improve upon the current post-exposure/overdose standard-of-care therapies to more effectively rescue victims of synthetic opioid intoxication.
2. Can be easily and rapidly deployed in the field, i.e., amenable to mass casualty use.
3. May be therapeutically effective against one or more of the synthetic opioids of concern listed above.
4. Has a mechanism of action other than antagonizing the mu-opioid receptor.

Section VII. Agency Contact

Scientific/Research Contact(s)

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: [email protected]

Financial/Grants Management Contact(s)

Jason Lundgren
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (240) 669-2973
Email: [email protected]

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Dave Yeung, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: (301) 761-7237
Email: [email protected]

Kiran Vemuri, Ph.D.
National Institute of Drug Abuse (NIDA)
Chemistry and Pharmacology Branch
Telephone: (301) 435-4446
Email: [email protected]